ArticlePharmacoEconomics2005
Pharmacoeconomic analyses using discrete event simulation.
Article in PharmacoEconomics, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- A Systematic Review of Modeling Approaches to Evaluate Treatments for Relapsed Refractory Multiple Myeloma: Critical Review and Considerations for Future Health Economic Models.PharmacoEconomics · 2024Pooled it
- Generating evidence to inform health technology assessment of treatments for SLE: a systematic review of decision-analytic model-based economic evaluations.Lupus science & medicine · 2020Pooled it
- Application of discrete event simulation in health care: a systematic review.BMC health services research · 2018Pooled it
- Cost-effectiveness of surgical interventions for the management of osteoarthritis: a systematic review of the literature.BMC musculoskeletal disorders · 2017Pooled it
- A Systematic Review and Critical Appraisal of Economic Evaluations of Pharmacological Interventions for People with Bipolar Disorder.PharmacoEconomics · 2017Pooled it
- Decision-analytic models to simulate health outcomes and costs in heart failure: a systematic review.PharmacoEconomics · 2011Pooled it
- Lowering the Barriers to the Appropriate Use of Individual-Level Simulation for Health Economic Evaluation.PharmacoEconomics · 2026Article
- Evaluating Semi-Markov Processes and Other Epidemiological Time-to-Event Models by Computing Disease Sojourn Density as Partial Differential Equations.Medical decision making : an international journal of the Society for Medical Decision Making · 2025Article
- Cost Effectiveness of Denosumab for Secondary Prevention of Osteoporotic Fractures Among Postmenopausal Women in China: An Individual-Level Simulation Analysis.Applied health economics and health policy · 2023Article
- Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China.Advances in therapy · 2022Article
- Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer.Drugs - real world outcomes · 2022Article
- Causal evidence in health decision making: methodological approaches of causal inference and health decision science.German medical science : GMS e-journal · 2022Review
- Predicting Hospital Resource Use During COVID-19 Surges: A Simple but Flexible Discretely Integrated Condition Event Simulation of Individual Patient-Hospital Trajectories.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2021Article
- Overview and Use of Tools for Selecting Modelling Techniques in Health Economic Studies.PharmacoEconomics · 2021Review
- Optimizing planning and design of COVID-19 drive-through mass vaccination clinics by simulation.Health and technology · 2021Article
- Burden of cardiovascular diseases associated with fine particulate matter in Beijing, China: an economic modelling study.BMJ global health · 2020Article
- Economic Evaluation of the 2016 Chinese Guideline and Alternative Risk Thresholds of Initiating Statin Therapy for the Management of Atherosclerotic Cardiovascular Disease.PharmacoEconomics · 2019Article
- Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States.The Annals of pharmacotherapy · 2019Article
- Model-Based Economic Evaluation of Treatments for Depression: A Systematic Literature Review.PharmacoEconomics - open · 2017Review
- Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To date, decision trees and Markov models have been the most common methods used in pharmacoeconomic evaluations. Both of these techniques lack the flexibility required to appropriately represent clinical reality. In this paper an alternative, more natural, way to model clinical reality--discrete event simulation--is presented and its application is illustrated with a real world example.A discrete event simulation represents the course of disease very naturally, with few restrictions. Neither mutually exclusive branches nor states are required, nor is a fixed cycle. All relevant aspects can be incorporated explicitly and efficiently. Flexibility in handling perspectives and carrying out sensitivity analyses, including structural variations, is incorporated and the entire model can be presented very transparently. The main limitations are imposed by lack of data to fit realistic models. Discrete event simulation, though rarely employed in pharmacoeconomics today, should be strongly considered when carrying out economic evaluations, particularly those aimed at informing policy makers and at estimating the budget impact of a pharmaceutical intervention.
Indexed as
Identifiers
15853433What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.